88 related articles for article (PubMed ID: 4039904)
21. Complement activation in cisplatin nephropathy.
Tamano M; Ohi H
Nephron; 1999; 81(4):442-3. PubMed ID: 10095183
[No Abstract] [Full Text] [Related]
22. Long-standing debate on cisplatin- versus carboplatin-based chemotherapy in the treatment of advanced non-small cell lung cancer.
Hotta K; Matsuo K
J Thorac Oncol; 2007 Jan; 2(1):96. PubMed ID: 17410021
[No Abstract] [Full Text] [Related]
23. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy.
Licciardello JT; Moake JL; Rudy CK; Karp DD; Hong WK
Oncology; 1985; 42(5):296-300. PubMed ID: 3875817
[TBL] [Abstract][Full Text] [Related]
24. Cisplatin-induced autonomic neuropathy.
Rosenfeld CS; Broder LE
Cancer Treat Rep; 1984 Apr; 68(4):659-60. PubMed ID: 6538810
[TBL] [Abstract][Full Text] [Related]
25. Acute Arterial Thrombosis during Postoperative Adjuvant Cisplatin-based Chemotherapy for Completely Resected Lung Adenocarcinoma.
Sato C; Okuda K; Tamiya H; Yamamoto K; Hoshina K; Narumoto O; Urushiyama H; Noguchi S; Amano Y; Watanabe K; Mitani A; Kage H; Tanaka G; Yamauchi Y; Takai D; Nagase T
Intern Med; 2018 Feb; 57(4):557-561. PubMed ID: 29225246
[TBL] [Abstract][Full Text] [Related]
26. [Acute myocardial infarction induced by lung cancer chemotherapy with cisplatin and etoposide].
Tsutsumi T; Ozawa Y; Kawakami A; Fujii H; Asamoto H
Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):413-7. PubMed ID: 2155588
[TBL] [Abstract][Full Text] [Related]
27. Cisplatin nephrotoxicity: symptomatic hypomagnesemia and renal failure.
Gomez Campdera FJ; Gonzalez P; Carrillo A; Estelles MC; Rengel M
Int J Pediatr Nephrol; 1986; 7(3):151-2. PubMed ID: 3804580
[TBL] [Abstract][Full Text] [Related]
28. Ectopic ACTH and cisplatin toxicity--a diagnostic dilemma.
Nandagopal L; Arias C; Pillai U; Osman-Malik Y
Am J Ther; 2014; 21(5):e154-6. PubMed ID: 23591027
[No Abstract] [Full Text] [Related]
29. Phase II study of high-dose dexamethasone-based association in acute and delayed high-dose cisplatin-induced emesis--JCOG study 9413.
Sekine I; Nishiwaki Y; Kakinuma R; Kubota K; Hojo F; Matsumoto T; Ohmatsu H; Yokozaki M; Goto K; Miyamoto T; Takafuji J; Kodama T
Br J Cancer; 1997; 76(1):90-2. PubMed ID: 9218738
[TBL] [Abstract][Full Text] [Related]
30. [Toxicity of cisplatin administered with hydration of 1-hour duration and forced diuresis].
Lopez M; Papaldo P; Perno CF; Di Lauro L; Barduagni A
Clin Ter; 1983 Nov; 107(3):207-13. PubMed ID: 6686503
[No Abstract] [Full Text] [Related]
31. How do things stand with cisplatin?
Check W
JAMA; 1978 Dec; 240(23):2521-2525. PubMed ID: 712945
[No Abstract] [Full Text] [Related]
32. [Cisplatin].
Ogawa M
Gan To Kagaku Ryoho; 1984 May; 11(5):1140-6. PubMed ID: 6326687
[No Abstract] [Full Text] [Related]
33. Can Carboplatin replace Cisplatin in small cell lung cancer?
Noronha V
Indian J Cancer; 2011; 48(4):452-3. PubMed ID: 22293259
[No Abstract] [Full Text] [Related]
34. [Dosage adjustment of metoclopramide for controlling vomiting induced by cisplatin: pharmacokinetic approach].
Brechot JM; Dupeyron JP; Guyon F; Delfour C; Delattre C; Lebeau B; Rochemaure J
Presse Med; 1988 Jun; 17(22):1147-9. PubMed ID: 2840652
[TBL] [Abstract][Full Text] [Related]
35. [Hyponatremia during treatment with cisplatin].
Peyrade F; Taillan B; Lebrun C; Bendini JC; Passerron C; Dujardin P
Presse Med; 1997 Oct; 26(32):1523-5. PubMed ID: 9435831
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of cisplatin in small cell carcinoma of the lung.
Levenson RM; Ihde DC; Huberman MS; Cohen MH; Bunn PA; Minna JD
Cancer Treat Rep; 1981; 65(9-10):905-7. PubMed ID: 6268297
[TBL] [Abstract][Full Text] [Related]
37. A phase II trial of high-dose cytarabine and cisplatin in previously untreated non-small cell carcinoma of the lung. A Piedmont Oncology Association Study.
White DR; Powell BL; Craig JB; Stuart RK; Schnell FM; Goldklang GA; Atkins JN; Jackson DV; Richards F; Muss HB
Cancer; 1990 Apr; 65(8):1700-3. PubMed ID: 2156598
[TBL] [Abstract][Full Text] [Related]
38. Results of the phase II EORTC study comparing paclitaxel/cisplatin with teniposide/cisplatin in patients with non-small cell lung cancer. EORTC Lung Cancer Cooperative Group.
Postmus PE; Giaccone G; Debruyne C; Sahmoud T; Splinter TA; van Zandwijk N
Semin Oncol; 1996 Oct; 23(5 Suppl 12):10-3. PubMed ID: 8941404
[TBL] [Abstract][Full Text] [Related]
39. [Peripheral neuropathy caused by cisplatin in patients with lung cancer].
Murata M; Yamaji Y; Futami H; Shimada Y; Fujita J; Hashimoto Y; Shiotani T; Irino S
Gan To Kagaku Ryoho; 1989 Jun; 16(6):2283-8. PubMed ID: 2544151
[TBL] [Abstract][Full Text] [Related]
40. [Early phase II study of FK352 in cisplatin-induced nephropathy. Niigata Prefecture FK352 Study Group].
Yoshizawa H; Suzuki E; Arakawa M
Gan To Kagaku Ryoho; 1998 Nov; 25(13):2085-94. PubMed ID: 9838911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
